Best Practices for the Implementation of Clinical Advances in HR-Positive/HER2-Negative Breast Cancer

Download these slides from an expert-led symposium reviewing updates in oral targeted therapy for HR-positive/HER2-negative breast cancer and implementation in clinical practice.
Allison Butts, PharmD, BCOP
Kristina F. Byers, PharmD, BCOP
Format: Microsoft PowerPoint (.ppt)
File Size: 988 KB
Released: March 30, 2022

Acknowledgements

Provided by ProCE, LLC in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

Related Content

Experts discuss current and emerging oral targeted therapies in early and advanced HR+/HER2- breast cancer, from Clinical Care Options (CCO)

Allison Butts, PharmD, BCOP Kristina F. Byers, PharmD, BCOP Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 3, 2022 Expired: May 2, 2023

Commentary on advances in oral targeted therapies for the treatment of early and metastatic breast cancer, adverse event management, and tools for adherence, from Clinical Care Options (CCO)

Allison Butts, PharmD, BCOP Kristina F. Byers, PharmD, BCOP Released: April 25, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings